Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd. covers the month of April 2023, with a specific reporting date of April 17, 2023. The document serves to disclose a corporate governance update regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the appointment of Andrew Singer to the Company's Board of Directors. The Board has determined that Mr. Singer qualifies as an "independent director" under NASDAQ Listing Rule 5605(a)(2).
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document focuses solely on the director appointment and its incorporation into specific registration statements (Forms S-8, F-3, and F-3MEF).
Key Facts for Investor Verification
- Andrew Singer was appointed to the Board of Directors on April 17, 2023.
- Mr. Singer is classified as an independent director per NASDAQ rules.
- This filing does not include financial results; investors should refer to recent Form 20-F or quarterly reports for financial data.
- The press release detailing this appointment is included as Exhibit 99.1.